ArticleEye (London, England)2015
Cost effectiveness of collagen crosslinking for progressive keratoconus in the UK NHS.
Article in Eye (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 37 citations in OpenAlex.
- Automated Triage for New Keratoconus Referrals Using Multimodal Deep Learning.Ophthalmology science · 2026Article
- The Future of Interventional Keratoconus Management: Perspectives on Integrating Epithelium-on Oxygen-Enriched Cross-Linking into Comprehensive Care Pathways.Therapeutics and clinical risk management · 2026Article
- Neural Network Prediction of Keratoconus in AIPL1-Linked Leber Congenital Amaurosis: A Proof-of-Concept Pilot Study.Journal of clinical medicine · 2025Article
- Pilot Programme for Keratoconus Screening and Management in Adolescents with Down Syndrome.Diagnostics (Basel, Switzerland) · 2025Article
- Progression of keratoconus in the contralateral eye following acute corneal hydrops: A retrospective study.PloS one · 2025Article
- Assessing Access to and Utilization of the Advanced Diagnostic and Management Equipment for Early Keratoconus in Public and Private Healthcare Facilities Across Nyanza and Western Kenya.Clinical optometry · 2025Article
- Cost-Effectiveness of Corneal Collagen Crosslinking for Progressive Keratoconus: A Brazilian Unified Health System Perspective.International journal of environmental research and public health · 2024Article
- The Lifetime Expenditure in People with Keratoconus in Saudi Arabia.Vision (Basel, Switzerland) · 2023Article
- Corneal Outcomes Following Cataract Surgery Using Ophthalmic Viscosurgical Devices Composed of Chondroitin Sulfate-Hyaluronic Acid: A Systematic Review and Meta-Analysis.Clinical ophthalmology (Auckland, N.Z.) · 2023Review
- Pediatric Crosslinking: Current Protocols and Approach.Ophthalmology and therapy · 2022Review
- The Safety Profile of FDA-Approved Epithelium-Off Corneal Cross-Linking in a US Community-Based Healthcare System.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- Machine Learning Algorithms to Detect Subclinical Keratoconus: Systematic Review.JMIR medical informatics · 2021Review
- KeratoDetect: Keratoconus Detection Algorithm Using Convolutional Neural Networks.Computational intelligence and neuroscience · 2019Article
- Review
- Comment on 'Cost effectiveness of collagen crosslinking for progressive keratoconus in the UK NHS'.Eye (London, England) · 2016Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundKeratoconus is a progressive degenerative corneal disorder of children and young adults that is traditionally managed by refractive error correction, with corneal transplantation reserved for the most severe cases. UVA collagen crosslinking is a novel procedure that aims to prevent disease progression, currently being considered for use in the UK NHS. We assess whether it might be a cost-effective alternative to standard management for patients with progressive keratoconus.
methodsWe constructed a Markov model in which we estimated disease progression from prospective follow-up studies, derived costs derived from the NHS National Tariff, and calculated utilities from linear regression models of visual acuity in the better-seeing eye. We performed deterministic and probabilistic sensitivity analyses to assess the impact of possible variations in the model parameters.
resultsCollagen crosslinking is cost effective compared with standard management at an incremental cost of £ 3174 per QALY in the base case. Deterministic sensitivity analysis shows that this could rise above £ 33,263 per QALY if the duration of treatment efficacy is limited to 5 years. Other model parameters are not decision significant. Collagen crosslinking is cost effective in 85% of simulations at a willingness-to-pay threshold of £ 30,000 per QALY.
conclusionUVA collagen crosslinking is very likely to be cost effective, compared with standard management, for the treatment of progressive keratoconus. However, further research to explore its efficacy beyond 5 years is desirable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.